Rohit Malik
Overview
Explore the profile of Rohit Malik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
4183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hosono Y, Niknafs Y, Prensner J, Iyer M, Dhanasekaran S, Mehra R, et al.
Cell
. 2023 Sep;
186(19):4254-4255.
PMID: 37714137
No abstract available.
12.
Kalra S, Malik R, Singh G, Bhatia S, Al-Harrasi A, Mohan S, et al.
Inflammopharmacology
. 2022 Jul;
30(4):1153-1166.
PMID: 35802283
Traumatic brain injury (TBI) is an important global health concern that represents a leading cause of death and disability. It occurs due to direct impact or hit on the head...
13.
Malik R, Kalra S, Bhatia S, Al Harrasi A, Singh G, Mohan S, et al.
Biomed Pharmacother
. 2022 Jun;
152:113168.
PMID: 35701303
Dementia is defined as a gradual cognitive impairment that interferes with everyday tasks, and is a leading cause of dependency, disability, and mortality. According to the current scenario, millions of...
14.
Kregel S, Malik R, Asangani I, Wilder-Romans K, Rajendiran T, Xiao L, et al.
Clin Cancer Res
. 2019 Mar;
25(13):4038-4048.
PMID: 30918020
Purpose: The bromodomain and extraterminal (BET)-containing proteins (BRD2/3/4) are essential epigenetic coregulators for prostate cancer growth. BRD inhibitors have shown promise for treatment of metastatic castration-resistant prostate cancer (mCRPC), and...
15.
Choi J, Verhaegen M, Yazdani S, Malik R, Harms P, Mangelberger D, et al.
Neoplasia
. 2019 Feb;
21(3):322-330.
PMID: 30797188
Studies on the efficacy of small molecule inhibitors in Merkel cell carcinoma (MCC) have been limited and largely inconclusive. In this study, we investigated the therapeutic potential of a potent...
16.
Khadirnaikar S, Kumar P, Pandi S, Malik R, Dhanasekaran S, Shukla S
Mol Carcinog
. 2018 Dec;
58(4):544-553.
PMID: 30520148
Kidney Renal Clear Cell Carcinoma (KIRC) is a significant cause of cancer-related deaths. Here, we aim to identify the LncRNAs associated with the immune system and characterise their clinical utility...
17.
Zhang Y, Pitchiaya S, Cieslik M, Niknafs Y, Tien J, Hosono Y, et al.
Nat Genet
. 2018 May;
50(6):814-824.
PMID: 29808028
The androgen receptor (AR) plays a critical role in the development of the normal prostate as well as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines...
18.
Gawronski A, Uhl M, Zhang Y, Lin Y, Niknafs Y, Ramnarine V, et al.
Bioinformatics
. 2018 Apr;
34(18):3101-3110.
PMID: 29617966
Motivation: Long non-coding RNAs (lncRNAs) are defined as transcripts longer than 200 nt that do not get translated into proteins. Often these transcripts are processed (spliced, capped and polyadenylated) and...
19.
Hosono Y, Niknafs Y, Prensner J, Iyer M, Dhanasekaran S, Mehra R, et al.
Cell
. 2017 Dec;
171(7):1559-1572.e20.
PMID: 29245011
Large-scale transcriptome sequencing efforts have vastly expanded the catalog of long non-coding RNAs (lncRNAs) with varying evolutionary conservation, lineage expression, and cancer specificity. Here, we functionally characterize a novel ultraconserved...
20.
Mahajan K, Malla P, Lawrence H, Chen Z, Kumar-Sinha C, Malik R, et al.
Cancer Cell
. 2017 Jun;
31(6):790-803.e8.
PMID: 28609657
The androgen receptor (AR) is critical for the progression of prostate cancer to a castration-resistant (CRPC) state. AR antagonists are ineffective due to their inability to repress the expression of...